免疫疗法和向疗法在胸膜上皮瘤中的有效性:系统性审查
Apostolos C Agrafiotis1,2, Mariana Brandão2,3, Thierry Berghmans2,3
1Department of Thoracic and Vascular Surgery, Antwerp University Hospital, University of Antwerp, B-2650 Edegem, Belgium.
Biomedicines
|October 28, 2023
概括
免疫检查点抑制剂 (ICI) 在治愈选项耗尽时,显示出作为治疗胸膜上皮瘤 (TET) 的潜力. 对瘤微环境因素的进一步研究可以预测治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 胸膜上皮瘤 (TET) 是一种罕见的前端中瘤.
- 手术是可切除TET的主要治疗方法;全身疗法用于晚期疾病.
- 新型治疗方法,如免疫检查点抑制剂 (ICI) 和向疗法正在对TET进行研究.
研究的目的:
- 系统地审查ICI在TET中的疗效和毒性.
- 评估TET的向治疗方法.
- 为了识别瘤微环境 (TME) 的元素,预测ICI在TET中的有效性.
主要方法:
- 在2023年2月使用Ovid Medline和SciVerse Scopus进行了系统的文献搜索.
- 包括的研究评估了ICI疗效,毒性,向疗法和TME预测因素.
- 从2944份获取的摘要中分析了31项研究.
主要成果:
- 在TET中ICI疗效显示整体应答率 (ORR) 从0%到34%,无进展生存期 (PFS) 为3.88.6个月.
- 伦瓦提尼布在胸腺癌 (TC) 中显示38%的ORR;其他向疗法显示的活性有限.
- 瘤微环境因素,包括瘤透的淋巴细胞和瘤突变负担,可以预测ICI的疗效.
结论:
- 免疫检查点抑制剂 (ICI) 是对精选的TET患者的潜在治疗选择.
- 在初始化疗后不适应治愈治疗的TET患者中,可以考虑ICI.
- 对TME生物标志物的进一步研究是有必要的,以优化TET中的ICI治疗.
相关概念视频
Tumor Immunotherapy
538
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
538
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K


